ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.
Alyson K. Myers, MD
Advertisement
Alyson K. Myers, MD, is a professor at Albert Einstein College of Medicine and associate chair of faculty mentoring and community engagement at Montefiore Einstein, department of medicine.
Articles by Alyson K. Myers, MD
Diabetes disparities drive unequal CGM access and amputation risk, highlighting the need to address social, provider, and policy barriers to equitable care.
At ADA 2026, Alyson K. Myers, MD, explains why knowing your community—and meeting patients where they are—is key to better diabetes outcomes and lower costs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care
2
Rituximab Matches Ocrelizumab in Head-to-Head MS Trial
3
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH
4
FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch
5